Save over 86% with Dacoplice. Dacoplice is manufactured in Europe and shipped from India. Same Pfizer medicine at huge discoun over Vizimpro
Manufacturing site for Dacoplice is exactly the same as Vizimpro for Europe: M/s. Pfizer Manufacturing Deutschland GmbH Betriebsstatte Freiburg Mooswaldallee 1 Freiburg - 79090 (Germany)
Vizimpro European product information showing same manufacturing site as Dacoplice
Information about Dacoplice (Dacomitinib):
Dacoplice is a brand name for dacomitinib, a medication used primarily in the treatment of non-small cell lung cancer (NSCLC). It is a targeted therapy that works by inhibiting the epidermal growth factor receptor (EGFR) tyrosine kinase, which is involved in the growth and spread of cancer cells. Dacomitinib is typically prescribed for patients with advanced or metastatic NSCLC who have certain genetic mutations or characteristics.
Product Highlights:
Dacoplice (dacomitinib) is a selective tyrosine kinase inhibitor that specifically targets the epidermal growth factor receptor (EGFR) pathway, which is crucial in the growth and proliferation of cancer cells in non-small cell lung cancer (NSCLC).
Primarily used for the treatment of advanced or metastatic NSCLC with specific EGFR mutations, particularly in patients who have not previously received EGFR TKI therapy.
Clinical trials have shown that dacomitinib can improve progression-free survival and overall survival in patients with EGFR-mutant NSCLC.
Key Ingredient:
Dacomitinib
Key Benefits:
Specifically targets and inhibits EGFR, which can slow or stop the growth of cancer cells in NSCLC.
Shown to be effective in patients with EGFR-mutated NSCLC, potentially improving survival rates and progression-free survival.
Oral administration simplifies the treatment regimen compared to intravenous options.
Direction of Use:
Typically, the recommended dose is 45 mg once daily, taken orally. It is essential to follow the specific dosing schedule and instructions provided by a healthcare professional.
Take the tablet at the same time each day with or without food. Swallow the tablet whole; do not crush, chew, or break it.
Dacomitinib Recommended Dose Reductions for Adverse Reactions
Dose Level
Dose (Once Daily)
First dose reduction
45 Mg Daily
Second dose reduction
30 Mg Daily
Thirddose reduction
15 Mg Daily
Safety Concerns:
Includes rash, diarrhea, nausea, loss of appetite, and mouth sores.
May include interstitial lung disease (ILD), liver problems, and severe skin reactions. Regular monitoring and prompt reporting of symptoms to a healthcare provider are crucial.
May interact with other medications, particularly those affecting liver enzymes. Inform your healthcare provider about all other medications you are taking.
Avoid Dacoplice (Dacomitinib) If:
You have a known hypersensitivity or severe allergic reaction to dacomitinib or any of its components.
You have a history of severe lung disease (e.g., ILD or pneumonitis) or significant liver dysfunction without appropriate management.
It is not recommended during pregnancy due to potential harm to the fetus. It is also advised to avoid breastfeeding while on this medication due to potential risks to the infant.
